At Adiso, we create medicines to treat inflammatory diseases, to improve the lives of patients and their families. We believe that current therapeutic approaches are often inadequate to halt disease progression or run the risk of burdening the patient with significant safety concerns.
To tackle these challenges, we are advancing an innovative, multi-modal pipeline of small molecules and single strain live biotherapeutic products all with novel mechanisms of action. Our approach is scientifically and clinically cutting edge in that it is both targeted and locally acting at the site of inflammation.
ADS051 is a first-in-class modulator of neutrophil activity which is nearing completion of a Ph1b study in moderate-to-severe ulcerative colitis (UC). Adiso is also developing ADS032, a novel small molecule that acts as a dual inflammasome inhibitor (NLRP3 & NLRP1), it has entered IND enabling studies for the treatment of respiratory and dermal inflammation. ADS024 (SS-LBP) has just completed a Phase 1b study for the prevention of recurrent CDI and is Phase 2 ready for our moderate ulcerative colitis (UC) trial.